Background. To compare efficacy and safety outcomes for patients enrolled in 2 prospective phase 3 ABSSSI clinical trials of dalbavancin (DAL) who received study drug only IV, with no switch to oral therapy, for a total duration of 10-14 days.
Methods. Both trials were double-blind, double dummy, randomized trials in which patients with ABSSSI were randomized to receive DAL 1g IV on Day 1 and 500 mg IV on Day 8 or Vancomycin (VAN) 1g (or 15mg/kg) IV every 12 hours (q12h) for at least 3 days with an option to switch to oral linezolid (L) 600 mg q12h to complete 10-14 days of therapy. In a pooled analysis, we identified patients who received ≥10 days of IV VAN/placebo study drug without being switched to oral therapy (oral placebo for patients in the DAL group and oral L in the VAN/L group). Efficacy and safety outcomes for this subset of patients were evaluated.
Results. 61/652 (9.4%) patients randomized to DAL completed ≥10 days of IV placebo compared to 54/651 (8.3%) of patients randomized to VAN/L who received ≥10 days of IV VAN. *nephrotoxicity defined as a 50% increase from baseline serum creatinine or an absolute increase in serum creatinine of 0.5 mg/dL
Conclusion. Patients with ABSSSI treated with DAL had similar clinical success rates at EOT compared to those treated with IV VAN alone. Compared to patients receiving DAL, patients who received IV VAN for ≥10 days had a tendency towards more TEAEs and more nephrotoxicity.
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